
The FDA has given the nod to Solodyn, the first minocycline productapproved for once-daily dosing in the treatment of inflammatorylesions of non-nodular moderate to severe acne vulgaris.Manufacturer Medicis claims that Solodyn is not bioequivalent toany other minocycline product and is the only extended-releaseminocycline in tablet form.